Biovail To Complete Sales Force Reorganization In April; Adds Specialty Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
Increased SG&A expenses associated with the sales force reorganization caused Biovail to miss its 2003 financial guidance. The company expects to out-license tramadol and once-daily metformin.